اليوم الأول - الجمعة 18 أكتوبر 2024 | ||
08.40 - 09.00 | Welcome and Introduction to EndoBridge 2024 | |
09.00 - 11.00 MAIN HALL |
||
09:00 - 09:30 | Management of Cushing disease | |
09:30 - 10:00 | Genetics of pituitary adenomas and their relevance in clinical care | |
10:00 - 10:30 | Approach to aggressive pituitary tumors | |
10:30 - 11:00 | TBC | |
11.00 - 11.20 | Coffee Break | |
11.20 - 12.50 | Interactive Case Discussion Sessions | |
HALL A | Pituitary | |
HALL B | Adrenal | |
HALL C | Neuroendocrine Tumors | |
HALL D | Male Reproductive Endocrinology | |
12.50 - 14.00 | Lunch | |
14.00 - 15.30 | Interactive Case Discussion Sessions | |
HALL A | Pituitary | |
HALL B | Adrenal | |
HALL C | Neuroendocrine Tumors | |
HALL D | Female Reproductive Endocrinology | |
15.30 - 15.50 | Coffee Break | |
15.50 - 17.50 MAIN HALL |
||
15:50 - 16:20 | Adrenal Insufficiency - common and rare causes – from biology to clinical care | |
16:20 - 16:50 | Updates on male hypogonadism and infertility | |
16:50 - 17:20 | TBC | |
17:20 - 17:50 | TBC | |
اليوم الثاني - السبت 19 أكتوبر 2024 | ||
09.00 - 11.00 MAIN HALL |
||
09:00 - 09:30 | Osteoporosis in children and adolescents | |
09:30 - 10:00 | Diabetes, obesity and bones | |
10:00 - 10:30 | Bone loss and fractures post denosumab discontinuation | |
10:30 - 11:00 | Goal directed therapy- BHOF- ASBMR position | |
11.00 - 11.20 | Coffee Break | |
11.20 - 12.50 | Interactive Case Discussion Sessions | |
HALL A | Diabetes | |
HALL B | Thyroid | |
HALL C | Bone and Calcium | |
HALL D | Obesity, Metabolism and Nutrition | |
12.50 - 14.00 | Lunch | |
14.00 - 15.30 | Interactive Case Discussion Sessions | |
HALL A | Diabetes | |
HALL B | Thyroid | |
HALL C | Bone and Calcium | |
HALL D | Obesity, Metabolism and Nutrition | |
15.30 - 15.50 | Coffee Break | |
15.50 - 17.50 MAIN HALL |
||
15:50 - 16:20 | Update on ATA pregnancy guidelines | |
16:20 - 16:50 | Update on ATA nodule guidelines | |
16:50 - 17:20 | Update on ATA cancer guidelines | |
17:20 - 17:50 | Treatment of subclinical thyroid disease | |
اليوم الثالث - الأحد 20 أكتوبر 2024 | ||
09.00 - 11.00 MAIN HALL |
||
09:00 - 09:30 | Phenotyping obesities: Reality or utopia | |
09:30 - 10:00 | Evidence and experience-based obesity pharmacotherapy | |
10:00 - 10:30 | Obesity management in preventing and treating MASLD | |
10:30 - 11:00 | GLP-1R agonists & cardiovascular outcomes in obesity without diabetes | |
11.00 - 11.20 | Coffee Break | |
11.20 - 13.20 MAIN HALL |
||
11:20 - 11:50 | Diabetes in pregnancy | |
11:50 - 12:20 | Revolutionizing diabetes management with once weekly insulins | |
12:20 - 12:50 | Technology in T2DM | |
12:50 - 13:20 | Adjunct therapies for type 1 diabetes | |
13.20 - 13.30 | Closing comments and adjourn |